EPIC Results Shed Light On First-Line Ponatinib Risk–Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase–chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news